Who Paid My Doc
Iryna Crescenze
Urology Columbus, OH Medical Doctor
NPI 1942507322 CMS profile 1392745
915 Olentangy River Rd, Columbus, OH 43212
General payments
$1,219
Research payments
$2,096
Ownership & investment interest
$0
Research they led as principal investigator
$154,397
Through program year 2024, Iryna Crescenze of Columbus, OH is reported in the CMS Open Payments database as having received $1,219 across 18 general payments and $2,096 in research payments paid to them. Separately, studies naming them as principal investigator received $154,397 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 55th percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
5 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2024 | General | $450 | 6 | |
| 2023 | General | $126 | 2 | |
| 2022 | General | $511 | 8 | |
| 2022 | Research | $2,096 | 1 | |
| 2019 | General | $131 | 2 |
Beside peers
- Iryna Crescenze
- Urology median
- Middle half of Urology
- National median
In program year 2025, general payments to Iryna Crescenze were reported at $0. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.
Show as a table
| Year | Iryna Crescenze | Urology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $131 | $480 | $147–$1,201 | $163 |
| 2020 | $0 | $246 | $87–$645 | $114 |
| 2021 | $0 | $358 | $111–$1,000 | $132 |
| 2022 | $511 | $476 | $143–$1,263 | $149 |
| 2023 | $126 | $560 | $168–$1,461 | $160 |
| 2024 | $450 | $563 | $170–$1,464 | $164 |
| 2025 | $0 | $629 | $190–$1,620 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 18 drugsPart D claims
668
Drug cost
$81,679
Branded share of claims
40.3%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Gemtesa Vibegron | Brand | 55 | $37,714 | |
| Myrbetriq Mirabegron | Brand | 58 | $30,687 | |
| Estradiol | Generic | 77 | $5,291 | |
| Methenamine Hippurate | Generic | 51 | $2,404 | |
| Gentamicin Sulfate | Generic | 83 | $2,223 | |
| Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst | Brand | 44 | $879 | |
| Solifenacin Succinate | Generic | 12 | $526 | |
| Oxybutynin Chloride Er Oxybutynin Chloride | Brand | 27 | $436 | |
| Tamsulosin Hcl | Generic | 33 | $323 | |
| Cephalexin | Generic | 52 | $233 |
The 10 drugs with the highest cost, of 18 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 81 billing codesPaid by Medicare
$102,220
Medicare patients
205
Services billed
7,227
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 72% | |
| Arthritis | 52% | |
| Depression | 40% | |
| Chronic kidney disease | 38% | |
| Diabetes | 34% | |
| Ischemic heart disease | 28% | |
| Cancer | 26% | |
| Osteoporosis | 20% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, onabotulinumtoxina, 1 unit J0585 | Office | 18 | 5,500 | $27,068 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
19 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Urology in Ohio
Related records
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.